Zentalis Pharmaceuticals, Inc. (ZNTL) · Insider trading
What Zentalis Pharmaceuticals's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$22.92M
1 insider, 2 trades
Sold, 12 months
$10.11M
4 insiders, 1% under a plan
Net, 12 months
+$12.81M
bought less sold
Latest filing
2026-10-01
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Walters Group10% owner | $22.92M | – | 2 | 2026-08-14 | 17,844,973 |
| Matrix Capital Management Company, LP10% owner | – | $9.97M | 1 | 2025-12-15 | – |
| Vultaggio VincentPAO and PFO | – | $109,890 | 6 | 2026-02-10 | 146,506 |
| Skvarka JanDirector | $103,200 | – | 1 | 2025-01-31 | 149,551 |
| Eastland Julia MarieDirector, CEO & President | $49,305 | $21,239 | 3 | 2026-02-09 | 79,133 |
| Bruns IngmarChief Medical Officer | $45,600 | $7,998 | 3 | 2026-02-09 | 33,332 |
| Lackner MarkChief Scientific Officer | – | $38,332 | 2 | 2025-02-03 | 512,856 |
| Myers Scott DunsethDirector | $29,400 | – | 1 | 2025-04-30 | 281,192 |
| Walker Luke NathanielDirector | $24,992 | – | 1 | 2025-01-31 | 86,681 |
| Paul AndreaChief Legal Officer | – | $22,623 | 1 | 2025-02-03 | 1,070,784 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-14 | Walters Group10% ownerwith Walters William Thurman, Walters Susan Berkley | Buy | 4,335,000 | 3.50 | $15.17M | 17,844,973 | Form 4 |
| 2026-02-10 | Vultaggio VincentPAO and PFO | Saleplan | 6,894 | 2.42 | $16,683 | 146,506 | Form 4 |
| 2026-02-09 | Eastland Julia MarieDirector, CEO & President | Sale | 889 | 2.39 | $2,125 | 79,133 | Form 4 |
| 2026-02-09 | Bruns IngmarChief Medical Officer | Sale | 335 | 2.39 | $801 | 33,332 | Form 4 |
| 2026-02-09 | Vultaggio VincentPAO and PFO | Saleplan | 3,379 | 2.39 | $8,076 | 153,400 | Form 4 |
| 2026-02-06 | Eastland Julia MarieDirector, CEO & President | Sale | 7,866 | 2.43 | $19,114 | 80,022 | Form 4 |
| 2026-02-06 | Bruns IngmarChief Medical Officer | Sale | 2,962 | 2.43 | $7,198 | 33,667 | Form 4 |
| 2026-02-06 | Vultaggio VincentPAO and PFO | Saleplan | 29,951 | 2.43 | $72,781 | 156,779 | Form 4 |
| 2026-02-03 | Vultaggio VincentPAO and PFO | Saleplan | 556 | 2.52 | $1,401 | 186,730 | Form 4 |
| 2026-02-02 | Vultaggio VincentPAO and PFO | Saleplan | 2,540 | 2.55 | $6,477 | 187,286 | Form 4 |
| 2025-12-31 | Walters Group10% ownerwith Walters William Thurman, Walters Susan Berkley | Buy | 6,459,973 | 1.20 | $7.75M | 13,509,973 | Form 4 |
| 2025-12-15 | Matrix Capital Management Company, LP10% ownerwith Goel David e. | Saleindirect | 7,500,000 | 1.33 | $9.97M | 6,459,973 | Form 4 |
| 2025-04-30 | Myers Scott DunsethDirector | Buy | 21,000 | 1.40 | $29,400 | 281,192 | Form 4 |
| 2025-02-06 | Bruns IngmarChief Medical Officer | Buy | 20,000 | 2.28 | $45,600 | 36,629 | Form 4 |
| 2025-02-03 | Paul AndreaChief Legal Officer | Sale | 13,230 | 1.71 | $22,623 | 1,070,784 | Form 4 |
| 2025-02-03 | Lackner MarkChief Scientific Officer | Sale | 14,368 | 1.71 | $24,569 | 512,856 | Form 4 |
| 2025-02-03 | Vultaggio VincentPAO and Interim PFO | Sale | 2,615 | 1.71 | $4,472 | 189,826 | Form 4 |
| 2025-01-31 | Eastland Julia MarieDirector, CEO & President | Buy | 28,500 | 1.73 | $49,305 | 28,500 | Form 4 |
| 2025-01-31 | Walker Luke NathanielDirector | Buy | 14,200 | 1.76 | $24,992 | 86,681 | Form 4 |
| 2025-01-31 | Skvarka JanDirector | Buy | 60,000 | 1.72 | $103,200 | 149,551 | Form 4 |
| 2025-01-02 | Lackner MarkChief Scientific Officer | Sale | 4,411 | 3.12 | $13,762 | 191,317 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
18 × grant or award
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-30 | Bruns IngmarChief Medical Officer | Grant or award A | +9,727 | 2.18 | 43,059 | Form 4 |
| 2026-06-16 | Myers Scott DunsethDirector | Grant or award A | +57,100 | – | 395,895 | Form 4 |
| 2026-06-16 | Walker Luke NathanielDirector | Grant or award A | +57,100 | – | 201,384 | Form 4 |
| 2026-06-16 | Johnson David MichaelDirector | Grant or award A | +57,100 | – | 307,521 | Form 4 |
| 2026-06-16 | Skvarka JanDirector | Grant or award A | +57,100 | – | 264,254 | Form 4 |
| 2026-06-16 | Kariuki EnochDirector | Grant or award A | +57,100 | – | 194,465 | Form 4 |
| 2026-05-26 | Campbell ShannonDirector | Grant or award A | +114,200 | – | 114,200 | Form 4 |
| 2025-06-17 | Myers Scott DunsethDirector | Grant or award A | +57,603 | – | 338,795 | Form 4 |
| 2025-06-17 | Kariuki EnochDirector | Grant or award A | +57,603 | – | 137,365 | Form 4 |
| 2025-06-17 | Johnson David MichaelDirector | Grant or award A | +57,603 | – | 250,421 | Form 4 |
| 2025-06-17 | Skvarka JanDirector | Grant or award A | +57,603 | – | 207,154 | Form 4 |
| 2025-06-17 | Walker Luke NathanielDirector | Grant or award A | +57,603 | – | 144,284 | Form 4 |
| 2025-02-03 | Eastland Julia MarieDirector, CEO & President | Grant or award A | +59,388 | – | 87,888 | Form 4 |
| 2025-02-03 | Bruns IngmarChief Medical Officer | Grant or award A | +16,629 | – | 16,629 | Form 4 |
| 2025-02-03 | Paul AndreaChief Legal Officer | Grant or award A | +934,041 | – | 1,084,014 | Form 4 |
| 2025-02-03 | Lackner MarkChief Scientific Officer | Grant or award A | +335,907 | – | 527,224 | Form 4 |
| 2025-02-03 | Vultaggio VincentPAO and Interim PFO | Grant or award A | +158,586 | – | 192,441 | Form 4 |
| 2024-11-13 | Myers Scott DunsethDirector | Grant or award A | +260,192 | – | 260,192 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.